Hiroshi Enaida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hiroshi Enaida has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Shigeo Yoshida
J-CREST (Japan Clinical REtina STudy Group), Kagoshima 890-8544, Japan
7 shared publications - Shintaro Nakao
Department of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan
5 shared publications Tatsuro Ishibashi
Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; and
5 shared publicationsKazuaki Kadonosono
3 shared publicationsAkifumi Ueno
Ohshima Hospital of Ophthalmology, Fukuoka, Japan
2 shared publicationsTakaaki Matsui
Ohshima Hospital of Ophthalmology, Fukuoka, Japan
2 shared publications
Latest Publications
- Open Access
- 26 April 2014
- Published by Springer Nature in BMC Ophthalmology
- Vol. 14 (1) , 55
Hyphema is a risk factor for failure of trabeculectomy in neovascular glaucoma: a retrospective analysis
Several retinal ischemic diseases can cause neovascular glaucoma (NVG). Trabeculectomy with mitomycin C (MMC) is a relatively better treatment modality in the management of eyes with NVG than other glaucoma surgeries. The aim of this study was to investigate the factors that may influence the outcome of trabeculectomy with MMC for NVG.
- 26 April 2014
- Published by Springer Nature in BMC Ophthalmology
- Vol. 14 (1) , 55
Open AccessHyphema is a risk factor for failure of trabeculectomy in neovascular glaucoma: a retrospective analysis
Several retinal ischemic diseases can cause neovascular glaucoma (NVG). Trabeculectomy with mitomycin C (MMC) is a relatively better treatment modality in the management of eyes with NVG than other glaucoma surgeries. The aim of this study was to investigate the factors that may influence the outcome of trabeculectomy with MMC for NVG.
- 1 November 2013
- Published by Wolters Kluwer Health in Retina
- Vol. 33 (10) , 2170-2174
QUANTITATIVE ANALYSIS OF VITREOUS AND PLASMA CONCENTRATIONS OF BRILLIANT BLUE G AFTER USE AS A SURGICAL ADJUVANT IN CHROMOVITRECTOMY
Purpose: To measure the concentration of brilliant blue G (BBG) in vitreous and plasma after use as a surgical adjuvant for staining and peeling of the internal limiting membrane to determine potential systemic adverse effects. Methods: This study was designed as a prospective, interventional, clinical, case series. Five eyes from five patients with macular hole or epiretinal membrane underwent BBG-assisted internal limiting membrane and epiretinal membrane removal. The vitreous samples were obtained and stored at the end of surgery in all five cases. The plasma specimens were extracted and stored at the end of the operation, after 4 hours, and after 7 days post operation. For BBG analysis of plasma and vitreous, high-performance liquid chromatography coupled with tandem mass spectrometric detection was used. Results: Brilliant blue G was not detected in plasma from all five cases at the three points of measurement. The mean vitreous BBG concentration was 34.5 ± 23.7 ng/mL (range, 11.3–70.9 ng/mL). Postoperative progress was good, and adverse effects were not observed in any of the five cases. Conclusion: Brilliant blue G, which remained at low levels in the vitreous cavity, was not found in the systemic blood flow after the operation. Thus, any adverse effects of systemic BBG would be avoided.
- 1 November 2013
- Published by Wolters Kluwer Health in Retina
- Vol. 33 (10) , 2170-2174
QUANTITATIVE ANALYSIS OF VITREOUS AND PLASMA CONCENTRATIONS OF BRILLIANT BLUE G AFTER USE AS A SURGICAL ADJUVANT IN CHROMOVITRECTOMY
Purpose: To measure the concentration of brilliant blue G (BBG) in vitreous and plasma after use as a surgical adjuvant for staining and peeling of the internal limiting membrane to determine potential systemic adverse effects. Methods: This study was designed as a prospective, interventional, clinical, case series. Five eyes from five patients with macular hole or epiretinal membrane underwent BBG-assisted internal limiting membrane and epiretinal membrane removal. The vitreous samples were obtained and stored at the end of surgery in all five cases. The plasma specimens were extracted and stored at the end of the operation, after 4 hours, and after 7 days post operation. For BBG analysis of plasma and vitreous, high-performance liquid chromatography coupled with tandem mass spectrometric detection was used. Results: Brilliant blue G was not detected in plasma from all five cases at the three points of measurement. The mean vitreous BBG concentration was 34.5 ± 23.7 ng/mL (range, 11.3–70.9 ng/mL). Postoperative progress was good, and adverse effects were not observed in any of the five cases. Conclusion: Brilliant blue G, which remained at low levels in the vitreous cavity, was not found in the systemic blood flow after the operation. Thus, any adverse effects of systemic BBG would be avoided.
- 1 October 2013
- Published by Wolters Kluwer Health in Retina
- Vol. 33 (9) , 1923-1930
CLINICAL EVALUATION AND FEASIBILITY OF CHANGING INTRAOPERATIVE VISIBILITY WITH A NOVEL VIEWING FILTER SYSTEM FOR HUMAN EYE
The study was conducted to develop a new viewing system as a clinical prototype that enables visibility during surgery. The system was composed of several filters attached to the microscope. This nonrandomized, retrospective, observational case series study involved 33 eyes from 32 patients who presented with various diseases and underwent surgery. The authors evaluated the changes in visualization focusing on controlling intraoperative visibility under air infusion and enhancing Brilliant Blue G staining focusing a sharp-cut filter Y (SCY). Visibility was compared under various surgical conditions, including cataract surgery, both with and without this system. Quantitative analysis of changes in intraoperative reflection including halation under air infusion and Brilliant Blue G intensity was carried out using the International Commission on Illumination 1976 (L*, a*, b*) color space method. A SCY reduced the reflection and halation by a maximum of 69.6%, when compared with use of no filter under air infusion (P Conclusion: The system improved intraoperative visibility under air infusion and the Brilliant Blue G staining intensity by use of SCY during vitrectomy.
- 1 October 2013
- Published by Wolters Kluwer Health in Retina
- Vol. 33 (9) , 1923-1930
CLINICAL EVALUATION AND FEASIBILITY OF CHANGING INTRAOPERATIVE VISIBILITY WITH A NOVEL VIEWING FILTER SYSTEM FOR HUMAN EYE
The study was conducted to develop a new viewing system as a clinical prototype that enables visibility during surgery. The system was composed of several filters attached to the microscope. This nonrandomized, retrospective, observational case series study involved 33 eyes from 32 patients who presented with various diseases and underwent surgery. The authors evaluated the changes in visualization focusing on controlling intraoperative visibility under air infusion and enhancing Brilliant Blue G staining focusing a sharp-cut filter Y (SCY). Visibility was compared under various surgical conditions, including cataract surgery, both with and without this system. Quantitative analysis of changes in intraoperative reflection including halation under air infusion and Brilliant Blue G intensity was carried out using the International Commission on Illumination 1976 (L*, a*, b*) color space method. A SCY reduced the reflection and halation by a maximum of 69.6%, when compared with use of no filter under air infusion (P Conclusion: The system improved intraoperative visibility under air infusion and the Brilliant Blue G staining intensity by use of SCY during vitrectomy.
- 1 January 2013
- Published by Wolters Kluwer Health in Retina
- Vol. 33 (1) , 244-246
NEW MICRO FORCEPS WITH HIGH UTILITY FOR VARIOUS USES IN MICROINCISION VITRECTOMY SURGERY
- 1 January 2013
- Published by Wolters Kluwer Health in Retina
- Vol. 33 (1) , 244-246
NEW MICRO FORCEPS WITH HIGH UTILITY FOR VARIOUS USES IN MICROINCISION VITRECTOMY SURGERY
- 1 November 2012
- p. 628-46
[Molecular targeting therapy for diabetic retinopathy].
- 1 July 2012
- p. 356-9
[Pathophysiology and diagnosis of diabetic retinopathy].